Analysts are slightly more optimistic about Veracyte's losses per share, but expect its revenue growth to slow down substantially compared to its historical 29% growth rate. The wider industry is expected to outpace Veracyte.
The absence of any insider transactions in the past three months doesn't reveal much. Low insider ownership and previous insider selling at Veracyte sparks less enthusiasm. Investors should be aware of potential risks associated with the company.
Gainers: •$Microvast(MVST.US)$+14.6% (In reaction to earnings) •$Sea(SE.US)$+11.3% (Q1 adjusted loss expands, revenue jumps) •$京東(JD.US)$+9.1% (beating top-line and bottom-line estimates for its latest quarter) •$Coinbase(COIN.US)$+6.3% (announces it is "slowing hiring so we can reprioritize our hiring needs against our highest-priority business goals") •$Heliogen(HLGN.US)$+5%(to restate Full Year 2021 Financials) •$Take-Two互動軟體件(TTWO.US)$+4.9% (de...
Gainers: •$Affirm Holdings(AFRM.US)$+36.4% (also announces multi-year extension of exclusive partnership with SHOP in the US) •$Robinhood(HOOD.US)$+22.9% (Emergent Fidelity discloses 7.6% stake; Sam Bankman-Fried CEO of crypto exchange FTX is majority holder in fund) •$奮進集團(EDR.US)$+20% (in reaction to earnings) •$Coinbase(COIN.US)$+13% (in sympathy with HOOD news) •$德納維製藥(DVAX.US)$+11.5% (to join ...
搞经济 抄底 加仓 :
I though I got the dip , till news out that ARK came on board. I know this is not the end.. Average Down^together 還以爲抄底了 知道木頭也買了。。那一瞬間我知道那不是低點了。。。哇c
$Veracyte(VCYT.US)$ Veracyte announced that it has begun rolling out its long-awaited nasal swab test for lung cancer at a limited number of clinical sites, as the company continues to accumulate data to support its future full commercial rollout. The company also published recent findings showing that the Percepta Genomic test can more accurately group patients based on their risk of developing tumors and suspicious lung nodules.
Veracyte股票討論區
專欄Today's Pre-Market Stock Movers: BMY, ADBE, MSTR, AZN and More
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA生物科學(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...
專欄Today's pre-market stock movers: TSLA, JPM, NVAX, CAG and more
• $Theravance Biopharma(TBPH.US)$ +15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln)
• $Amryt Pharma(AMYT.US)$ +11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome)
• $Green Brick Partners(GRBK.US)$ +7.3% (to join S&P SmallCap 600)
• $TransGlobe Energy(TGA.US)$ +6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock...
專欄Today's pre-market stock movers: SE, AMD, WMT, JD and more
• $Microvast(MVST.US)$ +14.6% (In reaction to earnings)
• $Sea(SE.US)$ +11.3% (Q1 adjusted loss expands, revenue jumps)
• $京東(JD.US)$ +9.1% (beating top-line and bottom-line estimates for its latest quarter)
• $Coinbase(COIN.US)$ +6.3% (announces it is "slowing hiring so we can reprioritize our hiring needs against our highest-priority business goals")
• $Heliogen(HLGN.US)$ +5%(to restate Full Year 2021 Financials)
• $Take-Two互動軟體件(TTWO.US)$ +4.9% (de...
專欄Today's pre-market stock movers: TSLA, TWTR, AFRM, DWAC and more
• $Affirm Holdings(AFRM.US)$ +36.4% (also announces multi-year extension of exclusive partnership with SHOP in the US)
• $Robinhood(HOOD.US)$ +22.9% (Emergent Fidelity discloses 7.6% stake; Sam Bankman-Fried CEO of crypto exchange FTX is majority holder in fund)
• $奮進集團(EDR.US)$ +20% (in reaction to earnings)
• $Coinbase(COIN.US)$ +13% (in sympathy with HOOD news)
• $德納維製藥(DVAX.US)$ +11.5% (to join ...
ARK's buys and sells (Dec.16)
ARK's buys
$Robinhood(HOOD.US)$$Nu Holdings(NU.US)$$Veracyte(VCYT.US)$$Personalis(PSNL.US)$$PagerDuty(PD.US)$$Quantum-Si(QSI.US)$
ARK's sells
$Iovance Biotherapeutics(IOVA.US)$$LivePerson(LPSN.US)$$3D系統(DDD.US)$
Veracyte announced that it has begun rolling out its long-awaited nasal swab test for lung cancer at a limited number of clinical sites, as the company continues to accumulate data to support its future full commercial rollout.
The company also published recent findings showing that the Percepta Genomic test can more accurately group patients based on their risk of developing tumors and suspicious lung nodules.
暫無評論